Initial evaluation of PET/CT with 18F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients

Summary

This first‐in‐man study was performed to evaluate the safety, whole‐body distribution, dose estimation and lesion accumulation of ¹⁸F‐FSU‐880, a newly‐developed probe targeting prostate‐specific membrane antigen (PSMA). Six prostate cancer patients with known metastatic lesions underwent serial whole‐body positron emission tomography/computed tomography (PET/CT) with ¹⁸F‐FSU‐880. Blood and urine were analyzed before and after PET/CT. Accumulation of ¹⁸F‐FSU‐880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole‐body effective dose were calculated using OLINDA/EXM software. ¹⁸F‐FSU‐880 PET/CT could be performed without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10^‐2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in one patient, whose bone metastases were well‐controlled and inactive. PET/CT with ¹⁸F‐FSU‐880 could be performed safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of ¹⁸F‐FSU‐880 PET/CT in the management of prostate cancer patients.

This article is protected by copyright. All rights reserved.

https://ift.tt/2LiRB7W